Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Plasma EGFR Mutation-positive Lung Cancer × icotinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 41 Lung Neoplasms 7 Brain Neoplasms 7 NSCLC 4 EGF-R Positive Non-Small Cell Lung Cancer 2 Adenocarcinoma of Lung 2 Plasma EGFR Mutation-positive Lung Cancer 1 Non-squamous Non-small Cell Lung Cancer 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small-Cell Lung 1 Neoplasms 1 Neoplasm Metastasis 1 Bronchial Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03346811 2017-11-17

CHALLENGE

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown

Plasma EGFR Mutation-positive Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡